Compare BBAI & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBAI | SVRA |
|---|---|---|
| Founded | 2020 | 2007 |
| Country | United States | United States |
| Employees | 579 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | N/A | 2009 |
| Metric | BBAI | SVRA |
|---|---|---|
| Price | $2.77 | $5.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $5.50 | ★ $7.33 |
| AVG Volume (30 Days) | ★ 23.4M | 1.8M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.89 | N/A |
| Revenue Next Year | $11.71 | $430.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.59 | $2.43 |
| 52 Week High | $9.39 | $7.01 |
| Indicator | BBAI | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 35.34 | 44.24 |
| Support Level | N/A | $4.77 |
| Resistance Level | $4.44 | $5.43 |
| Average True Range (ATR) | 0.18 | 0.29 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 19.57 | 27.22 |
BigBear.ai Holdings Inc is a provider of mission-ready artificial intelligence (AI) technology originally founded to serve defense and national security mission customers. The Company provides Edge AI-powered decision intelligence solutions, including artificial intelligence and machine learning, generative AI, data science, computer vision, biometrics, cyber, cloud solutions, and systems integration. Customers rely on its predictive analytics capabilities in mission-based operating environments. Its solutions are organized into five markets, including Supply Chain & Logistics Solutions, Cybersecurity Solutions, Autonomous Systems Solutions, Digital Identity Services, and the Ask Sage Platform.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).